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AbstrACt
Introduction Kidney disease is common, affecting up 
to 1 in 10 of the adult population, and the numbers are 
expected to rise over the next decade. There are three 
main treatments that are available to patients with kidney 
disease: transplantation, dialysis and supportive care 
without dialysis. Dialysis can occur in a dialysis unit or 
in a person’s home, but unit-based dialysis remains the 
most common initial treatment for patients in Wales. This 
is a cause for concern as most studies suggest that it is 
associated with the lowest quality of life and the highest 
mortality, and is a more expensive treatment option.
This study aims to identify the factors that lead to patients 
choosing unit-based haemodialysis rather than home-
based dialysis with a view to informing future changes in 
patient education and service commissioning in Wales. 
A secondary aim is to determine if the co-production of 
research leads to more sustainable services.
Methods and analysis This mixed-method study taking 
place between October 2018 and September 2020 will use 
a sequential explanatory design whereby the descriptive 
quantitative cross-sectional analysis of linked health and 
administrative data sets inform qualitative data collection 
from patients, carers and health and care professionals. 
Qualitative findings will be used to interpret or explain 
quantitative descriptive results. Additional strands to 
the study include a review of materials and education 
provided to patients and an economic review of treatment 
modalities.
Ethics and dissemination The study will be conducted 
in accordance with the principles expressed in the 
Declaration of Helsinki. It has full approval from Health and 
Care Research Wales Research Ethics Committee #5. As 
a co-productive study involving patients, clinicians, third 
sector partners and academics, findings from this study 
will be shared on a continual basis. Study results will be 
published in peer-reviewed journals and presented at 
national and international conferences.
IntroduCtIon
It is estimated that the total cost of chronic 
kidney disease (CKD), in England in 2009 
to 2010 was between £1.44 and £1.45 billion, 
which equates to approximately 1.3% of all 
National Health Service (NHS) spending in 
that year.1 2 The National Institute for Health 
and Care Excellence3 estimated approxi-
mately 7000 excess strokes and 12 000 excess 
myocardial infarctions occurred in people 
with CKD in 2009 to 2010 (relative to an 
age-matched and gender-matched popula-
tion without chronic kidney disease), with 
an estimated cost of between £174 and 
£178 million.2
Incidence and prevalence of dialysis is 
higher in Wales than in other parts of the 
UK and despite an estimated 30% of patients 
being suitable for home therapies4 only 15% 
in Wales receive peritoneal dialysis and only 
6.9% home haemodialysis5 with significant 
variation in patient modality choice across 
the country. Previous systematic reviews6 7 
and single centre studies8 9 have identified a 
number of potentially modifiable factors that 
influence patient choice. These include peer 
strengths and limitationsof this study
 ► Principles of co-production mean that in this study 
National Health Service staff, patients, carers and 
other organisations will be working with academics 
to undertake research.
 ► The mixed-methods sequential explanatory design 
employed in this study is likely to provide both 
breadth and depth to our understanding of dialysis 
choices.
 ► The small sample for the qualitative study will not 
capture all aspects of patient choice.
 ► Wales is a small country (population 3 million) and 
healthcare is a fully devolved area of policy, which 
provides a manageable closed-system for study, and 
findings can rapidly change practice and improve 
patients care.
 ► There is a limited contemporary economic evidence 
base of kidney dialysis; therefore, this study ad-
dresses a knowledge gap in the literature.
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influence, timing of information, treatment flexibility, 
quality of life and a desire to maintain the status quo. 
Though of interest, the findings of these studies may not 
be directly applicable to pre-dialysis patients in Wales. 
Of note, none of the studies were based in the UK, and 
only one study focused on pre-dialysis patients. Other 
countries have significantly different healthcare systems 
to the UK, with different geographical constraints and 
different financial incentives/disincentives for home 
therapies as well as different modes of delivering pre-di-
alysis education.
The most comprehensive qualitative study of deci-
sion-making was recently undertaken in New Zealand 
(NZ)8 9 and concluded that the level of support avail-
able and socioeconomic status were key determinants 
of whether patients chose a home therapy. It is not clear 
whether the same situation applies in Wales since NZ is 
unique in terms of the number of patients dialysing at 
home (50% vs 22% in Wales). Of note, it was found that 
ethnicity and low household income was associated with 
lower preferences for a home therapy. However, patients 
in NZ choosing home therapies suffer out of pocket costs 
which is not the case in Wales.10
rationale
None of the studies reviewed8 10–15 have combined clin-
ical and socio-demographic data collection with quali-
tative study. Thus far, no studies have been undertaken 
in collaboration with service commissioners with the 
prespecified aim of bringing about optimal outcomes in 
patients by understanding their current choice of treat-
ment, so that optimal treatment decisions are made in 
the future. We feel there is a pressing need for this, and 
in Wales we have a unique opportunity to collaborate with 
the service commissioners to both inform and directly 
influence patient care.
Both The National Institute for Clinical Excellence 
(NICE) and the Welsh Renal Clinical Network (WRCN - 
who commission renal services in Wales) have recognised 
that too many patients are starting dialysis via unit-based 
haemodialysis (UHD). Given the current financial crisis 
that the NHS is facing, it is particularly worrying that the 
least cost-effective and worst therapy in terms of quality of 
life (QOL) remains the the most common choice in Wales. 
NICE have published two separate reports outlining the 
potential benefits of using home therapies.16 17 The NICE 
report on home dialysis suggested that up to 15% of all 
haemodialysis patients in the UK would be suitable for 
home-based haemodialysis while the NICE costing review 
of peritoneal dialysis (PD) suggested that up to 50% of 
patients would be suitable for PD. Home dialysis (and 
particularly short, daily home dialysis) has been shown to 
improve both mortality and quality of life, with observa-
tional studies and one randomised trial finding that more 
frequent dialysis improves outcomes.18 NICE and the 
commissioners of the service in Wales (WRCN) therefore 
agree that we need to increase the number of patients 
opting for a home therapy rather than UHD.
More recently, the WRCN published its delivery plan 
for 2016 to 2020. The renal network emphasise the need 
to make home therapies available to as many patients as 
possible who cannot have a pre-emptive transplant. Of 
note, the network strategy highlights that UHD should 
be a default option only when pre-emptive transplant and 
home therapies have been actively excluded.
As well as improving patient outcomes, reducing the 
number of patients on UHD may confer an economic 
benefit. This again has been highlighted by NICE, with 
an estimated saving for NHS England of £20 million per 
annum if home therapy was optimised.17 Even a more 
conservative estimate of 1% in the number of PD patients 
was estimated to save £4 million over 5 years.
Project description
This is a 2 year mixed method co-productive study inte-
grating analysis of the NHS electronic renal patient 
records database, documentary analysis of the current 
education programme in each renal unit, qualitative 
interviews with patients, unpaid carers and professionals, 
and health economics rapid review and analysis (see 
figure 1).
Aims and objectives
The aim of the study is to develop a better understanding 
of the factors that impact treatment choices across Wales, 
and specifically to delineate why so many patients default 
to UHD rather than choosing therapies that offer better 
survival, better QOL and deliver better public value.
A secondary aim is to look at the sustainability of current 
and proposed alternative service provision.
1. To investigate the factors that impact on the dialysis
choices made by patients with CKD in Wales.
2. To gain a comprehensive understanding of current
pre-dialysis education across Wales to highlight modifi-
able factors that might be addressed.
3. To assess the current cost to the NHS of dialysis treat-
ment options.
4. To assess the efficacy of co-productive research in ser-
vice improvement.
A list of the research questions are set out in figure 2.
MEthods And AnAlysIs
theoretical framework
This study is informed by a theoretical framework 
contained within the Making Good Decisions in Collab-
oration (MAGIC) shared patient decision-making 
intervention. The programme was developed for the 
UK NHS in 2010 designed to test and identify the best 
ways to embed shared decision-making into routine 
primary and secondary care using quality improvement 
methods.19 While many clinicians feel that they already 
involve patients in decisions about their care, shared 
decision-making differs from usual practice by building 
relationships through the clinical encounter so that infor-
mation is shared and patients are supported to deliberate 
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Figure 1 Study design. GP, general practitioner; NHS, National Health Service.
and express their preferences and views during the deci-
sion-making process.20 The MAGIC model (figure 3) 
provides a path to shared decision-making which is based 
on choice, option and decision talk underpinning the 
research aims of this study.
The most fundamental learning point from evaluations 
of the MAGIC programme21 is that no single intervention 
will succeed in isolation and that effective shared deci-
sion-making requires a range of interventions working 
together holistically across healthcare settings.
Methods
In summary, there are five strands to this study including 
co-production as an overarching process. The cohort for 
all elements of the study however, will be taken from the 
all-Wales renal electronic patient database that contains 
records on all patients in Wales who are under secondary 
care nephrology follow-up (including prevalent dial-
ysis patients, incident dialysis patients and pre-dialysis 
patients). For convenience we explain each strand sepa-
rately below.
Patient and public involvement (co-production)
The principles of co-production used in this study mean 
that from inception to dissemination, academics work 
together with those who provide and use services to 
improve services through research (figure 4).
To facilitate the co-production we will identify key 
members of the renal teams and work closely with the 
WRCN to deliver training via presentations at the National 
Chronic Kidney Disease meetings and the National Home 
Therapies meetings. In particular, we will work closely 
with the clinical nurse specialists based in each of the 
five renal units across Wales who have a critical role in 
supporting patient decision-making. We will have detailed 
conversations with other multidisciplinary team members 
and clinicians to tell them about the study and to under-
stand more about the ways they work so that we can inte-
grate the research activities appropriately across the five 
sites. We will also undertake extensive patient and public 
engagement throughout, using co-production in the 
study design, set-up and implementation, sharing interim 
data with key stakeholders – patients, carers, professionals 
and members of the public with important perspectives.
The co-productive approach will be evaluated through 
reflections gathered from all those involved in its co-pro-
duction and framed within the MAGIC approach. The 
evaluation will be iterative through a systematic, repetitive 
and recursive process taking place as an integral part of 
the study based on the guidance for reporting involvement 
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Figure 2 Research questions. ASCOT, Adult Social Care 
Outcomes Toolkit.
Figure 3 The magic framework. COD, Choices Options and Decisions.
Figure 4 Co-production.
of patients and public (GRIPP2) international guidance 
for reporting of patient and public involvement in health 
and social care research.22
documentary analysis of current patient education materials 
and practices
Documents, resources and information on how educa-
tion is delivered to patients and carers will be collected 
from each site. Using relevant concepts from the MAGIC 
framework, we will undertake a comparative content 
analysis to identify and compare the topics and content, 
mode of delivery and range of resources used in renal 
units across Wales. Using NVivo qualitative data software, 
we will deploy an inductive content23 analysis approach 
to assessing current education programme materials and 
practices, and decision-making procedures followed in 
Welsh renal centres.
Clinical audit data
The qualitative element will be a cross-sectional study 
making use of the Secure Anonymised Information 
Linkage (SAIL) databank to link clinical and socio-demo-
graphic data. The databank allows sourcing, accessing, 
linking and analysing of health and whole population 
data all within a governed infrastructure that is safe and 
secure. Renal patient data will be extracted from the elec-
tronic patient record, which has already been embedded 
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in SAIL. This will include gender, age, postcode, comor-
bidity (Charlson comorbidity score),24 frailty (Rockwood 
Clinical Frailty Scale score). Clinical and socio-demo-
graphic data will be extracted from the renal electronic 
patient record, which has been embedded into the SAIL 
databank. The SAIL databank allows linkage and analysis 
of pseudo-anonymised routinely collected data in a data 
safe-haven. The data will include gender, age, postcode, 
comorbidity (Charlson comorbidity score),24 frailty (Rock-
wood Clinical Frailty Scale score),25 renal function, quality 
of life data (EQ-5D-5L score).26 Data on the shared deci-
sion-making process will be extracted from our all-Wales 
shared decision-making database which has also been 
integrated with the SAIL databank. This will include data 
on which treatments were discussed with patients (and if 
not why not), which treatments were chosen (and why) 
and which treatments were not chosen (and why). We 
will augment this data from the renal electronic patient 
record by linkage with primary and secondary care data 
– to identify healthcare utilisation patterns – for instance
frequency of hospitalisation, use of primary care services 
and visits to accident and emergency departments. Anal-
ysis will be undertaken using multiple (logistic) regres-
sion techniques using SPSS software built into the secure 
SAIL environment. We will take a p value of <0.05 to indi-
cate significance in the absence of multiple comparisons. 
We will describe 95% CIs.
health economics
We will undertake a rapid review of economic evidence 
to identify previous published costs of different models 
of dialysis. Economic specific electronic databases will be 
searched including; the centre for reviews and dissemi-
nation (CRD) Database, NHS economics evaluation 
database (NHS EED) and health technology assessment 
(HTA) database. Evidence extracted will be used to 
inform a budget impact analysis, and a high-level Markov 
model,27 if there is sufficient data to populate the model. 
The costs of the different dialysis options for the budget 
impact analysis will also be informed by providers of dial-
ysis treatment in Wales, such as Welsh Health Specialised 
Services Committee, WRCN and further contacts they 
suggest. The budget impact analysis will be performed 
from a NHS and social care perspective.
Cost-consequence analysis is a variant of cost-effec-
tiveness analysis in which an array of consequences/ 
outcomes (eg, health related quality of life) and costs (eg, 
health service use costs) are presented,28 comparing the 
two treatment modalities (intervention group vs control 
group) in a disaggregated form, without combining these 
into a cost-effectiveness ratio or a cost-utility ratio.29 This 
type of analysis lists the components of an intervention, 
without making judgements of their relative importance, 
the verdict is left to the decision maker.
In this cost-consequence analysis, we will present 
outcomes as the frequency and costs of healthcare use of 
renal patients gathered from the SAIL databank. In order 
to answer if different dialysis pathways result in different 
service use, a cohort of established patients, that is those 
who have been on their chosen pathway for 3 months or 
more will be identified from the database. We will focus 
on the three pathways of; home, unit and peritoneal 
dialysis.30 The time-horizon for the analysis will be 1 year, 
using a NHS and social care perspective. Information on 
comorbidities will also be gathered to explore if this has 
an effect on service use.
To explore the sustainability of current models and 
how resources could be transferred to the social care 
sector to increase the uptake of home therapies, health 
economics specific questions will be added to staff and 
patient interviews. Staff will be asked about service 
provision and resources, and the potential for the social 
sector to support or change current provision. Patients 
will be asked about productivity losses through changed 
employment, costs of attending dialysis (eg, transport 
and parking) and if relevant changes to carer or family 
member employment if they help the patient to attend 
dialysis at a hospital or unit (eg, taking annual leave, 
reducing hours or repaying the time taken by working 
additional hours at a later date).
Qualitative interviews
We will interview a minimum of 40 patients and a 
minimum of 40 unpaid carers from across Wales. Not all 
patients have unpaid carers so it is likely that not all of 
the interviews will be with patient/carer dyads. Of the 
3000 patients on the electronic record who have made 
a treatment choice, approximately 20% to 25% choose 
a home therapy (n=750), 2250 opting for something 
else and at least 1 in 5 of these will be undecided (450 
approximately). From the total cohort, we will construct 
a maximum variation sample including from those who 
were eligible for home therapy and chose a different 
treatment, or were undecided in the initial sample for 
interviews across each of the renal units. We will also 
include patients over 18 who have made a decision and 
started therapy. Participants will be purposively sampled 
to ensure a wide range of perspectives and experiences. 
We can map the overall number with other criteria such 
as deprivation scale, treatment option, time on dialysis 
and eligibility for home therapy so we will aim to include 
additional characteristics of interest in the sample (such 
as; currently on treatment of choice; men; women; older; 
younger; multiple comorbidities, socially deprived, etc). 
Data collection continue until data saturation is reached.
The process for recruiting patients and carers to inter-
view is set out in figure 5.
Approximately 55 to 60 health and social care profes-
sionals currently working in the renal centres are involved 
in patient decision-making. We will interview a minimum 
of 20 professionals working across Wales (eg, doctors, 
nurses, social workers, psychologists, dieticians, occupa-
tional therapists, etc) individually and in focus groups. 
The process to engage and recruit professionals is co-pro-
ductive: professionals will be working closely with the 
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Figure 5 Recruitment process for patients and carers.
research team, the WRCN is a co-partner and the Lead 
Nurse is a member of the study team.
We will create a sample of the various renal team 
members that is representative of renal units across 
Wales. The focus groups and interviews will explore the 
values, preferences, experiences and expectations and 
anticipated outcomes from a professional perspective of 
patient decision-making in making dialysis choices. These 
focus groups and interviews will also help put emerging 
findings from the patient and carer interviews into 
context and contribute to the process of data integration 
and data analysis.
Digital recordings of interviews will be uploaded into 
NVivo, classified and coded. Codes will be created to 
link patients with their unpaid carers and professionals 
from their respective renal centre. We will use framework 
analysis to organise and analyse data – using the MAGIC 
framework as the organising mechanism mapped onto 
the different treatment pathways and decisions made by 
patients.19
All participants – patients, carers and professionals – 
will be given detailed written information on the study 
and will be asked to sign a consent form indicating their 
willingness to participate. Anonymity will be assured to 
participants. We will expressly ask participants for their 
anonymised data to be used for all purposes (in this 
study, to be stored for use in further studies, for teaching 
and training). Participants retain the right at all times 
to withdraw from the study at any time and patients will 
be assured that withdrawal will have no impact on their 
current or future treatment.
data integration
Data integration will occur at a number of levels using 
the MAGIC framework19 and as the underpinning mech-
anism for integration organised by treatment pathways 
and decisions. Qualitative data from patients and unpaid 
carers will for example be used to explain in more 
nuanced detail the patient and unpaid carer reasoning 
and explanations underpinning the different treatment 
decisions recorded in the patient database. Documen-
tary analysis of patient education programmes will for 
example be used to explain any obvious differences in 
the way programmes are delivered and any trends in 
promoting treatment options by centre. Professional 
interviews will also be used to compare the clinical and 
patient experiences. Drawing on anonymised cases from 
the patient interviews, we will develop a small number of 
scenarios to put to professionals, looking for any evidence 
of any conscious or unconscious biasses in recommended 
treatment options that may influence patient deci-
sion-making, as well as highlighting any issues for context 
such as resources and availability of treatments in specific 
centres. Data from the qualitative study will help inform 
the economic investigation, for example, whether it may 
be beneficial shift resources from health to social care 
and what types of costs these might be.
EthICs And dIssEMInAtIon
Ethical issues
We have considered the following ethical issues in 
designing this study:
1. Protection of individual medical information. For clin-
ical and economic database analyses, routinely collect-
ed clinical data has already been entered into the SAIL 
databank which is pseudo-anonymised (personally 
identifiable information fields within a data record are 
replaced by one or more artificial identifiers or pseud-
onyms). In this study, we will extract aggregate data for 
our analysis - so no patient identifiable data is held.
2. Protection of identifiable participant information.
Only the minimum information necessary to contact 
and interview participants will be collected.
3. Participant consent to be interviewed. Eligible pa-
tients will be invited to enter the study by renal unit 
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multidisciplinary team members who are known to the 
patients. We will use standardised protocols to ensure 
that patients are identified sensitively and given infor-
mation in a suitable way and at a suitable time. Prior 
to interview, patients and carers will be fully consent-
ed. At each stage of the recruitment process (figure 5) 
participants will have the opportunity to ask questions, 
consider their participation or withdraw with no con-
sequences. We have protocols in place for supporting 
field researchers including lone worker policies.
4. There is the possibility of patients and carers sharing
details which might cast light on the nurse and clinical
practices, therefore the patient interviews will be an-
onymised, and data shared back in a way that will not
identify either patients, carers or professionals.
5. There is a small possibility that the clinical teams will
feel that their practices are under unwanted scrutiny,
we will work with the renal teams throughout to build
good working relationships and positively encourage
the teams to share any concerns with us.
6. Full interview safeguards and protocols will be put in
place to ensure that there is no undue pressures on the
patients and carers during interview. Participants will
be offered a courtesy follow-up call and the research
team will disengage.
7. Any serious concerns for the safety of any participants
will be processed following the safeguarding policy in
the respective organisation who provides care for the
person. We will make this point clear in the consent
process.
8. Data management. There are multiple organisations
working co-productively on this study. We have de-
signed the study and developed specific General Data
Protection Regulation compliant protocols to ethically
and safely collect and store data and to ensure that no
personally identifiable data is shared between parties.
dissemination and impact
As a co-productive study involving patients, clinicians, 
third sector partners and academics, findings from this 
study will be shared on a continual basis. Responses from 
partners to findings are an intrinsic part of the evolution 
of co-production research. Our collaboration with the 
WRCN, means that we are able to rapidly disseminate our 
findings and influence patient care and service commis-
sioning. We speculate that the findings of our study may 
lead to the following changes:
 ► Incorrect patient assumptions about disease/therapy/
prognosis: If we find that patient’s perception of their 
disease and illness trajectory differs from their clini-
cian’s views then we will use the WRCN to overhaul 
the current pre-dialysis education programme. It is 
likely that the delivered information (and the way 
in which it is delivered) needs to be changed. This 
may include giving information earlier (and more 
gradually) as well as the use of multimedia tech-
nology. We will use the patient and carer interviews 
to help develop an education process that better 
elicits patients’ preferences and values so they can be 
matched to treatment
 ► Lack of carer/support network: If we find that social 
isolation is a factor that determines treatment choice, 
then together with the WRCN we will explore the role 
of utilising the social care sector for example, trans-
ferring costs from the healthcare sector to paid carers 
(this may form the basis of a future health economic 
study).
 ► Accommodation problems/concerns about cost: 
Lack of appropriate housing may prove to be one 
of the factors that limits treatment choice in Wales. 
In regions where this is the case we will look at the 
role of third sector in supporting patients to access 
benefits/re-housing (eg, employing benefits support 
officers). The WRCN has previously worked alongside 
third sector organisations to provide a youth worker 
to support younger patients come to terms with their 
illness and it may be that we need to follow the same 
model to support vulnerable older patients. Such an 
approach is likely to prove significantly cost-effective 
if it leads to more patients choosing to have dialysis 
at home.
 ► Variation between clinical teams regarding patient 
selection for home therapy: If we confirm significant 
variation in care between clinical teams, then (via 
the established quality and patient safety process) 
the WRCN will develop robust guidelines for clinical 
teams with standardised criteria defining which clin-
ical conditions preclude a home therapy. Given that 
the unique position that the WRCN holds as a clini-
cally led commissioning network with a track record 
of rapid service change, we feel that it is entirely 
feasible to expect that the findings of our study can 
rapidly change practice and improve patients care 
across Wales.
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